. Author manuscript; available in PMC: 2015 Mar 19.

Published in final edited form as: J Steroid Biochem Mol Biol. 2013 Jan 10;136:313–320. doi: 10.1016/j.jsbmb.2013.01.002

Table 3.

Maternal and Neonatal 25(OH)D Status by Treatment Group

Total Circulating 25(OH)D, ng/mL, Mean (SD)	Control	2000 IU	4000 IU	p-value (overall)	p-value (2000 vs. control)	p-value (4000 vs. control)
Baseline	24.6 (10.9)	23.2 (8.6)	22.8 (9.7)	0.21	> 0.05	> 0.05
Within 6 weeks of delivery	30.7 (14.1)	37.1 (14.7)	41.9 (16.2)	<0.0001	< 0.001	< 0.0001
Neonatal/cord blood	18.2 (10.1)	21.2 (11.1)	25.4 (12.9)	<0.0001	> 0.05	< 0.0001
Maternal 25(OH)D ≥32 ng/mL, %	57/110 (51.8)	138/201 (68.7)	147/193 (76.2)	<0.0001	<0.0001	<0.0001
Maternal 25(OH)D ≥40 ng/mL, %	39/110 (35.5)	98/201 (48.8)	121/193 (62.7)	<0.0001	<0.0001	<0.0001
Neonatal 25(OH)D ≥20 ng/mL, %	31/79 (39.2)	96/165 (58.2)	120/158 (76.0)	<0.0001	0.0007	<0.0001
Neonatal 25(OH)D ≥32 ng/mL, %	10/79 (12.7)	25/165 (15.2)	41/158 (26.0)	0.020	0.33	0.014

Continuous measures compared between dose groups using multivariable linear regression to adjust for study and participant race (excluding “Other”); pairwise comparisons against control performed using Dunnett's procedure. Dichotomous measures compared between dose groups using multivariable logistic regression to adjust for study and participant race (excluding “Other”).